Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lobeglitazone
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Aclipse Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Aclipse gains worldwide rights to develop CKD’s M107 (lobeglitazone), an oral, small molecule, for gastroparesis and additional indications.
Product Name : M107
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : Lobeglitazone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Aclipse Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CKD-510
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,305.0 million
Deal Type : Licensing Agreement
Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule
Details : Under the agreement, Novartis will have global exclusive rights to develop and commercialize CKD-510, a small molecule histone deacetylase 6 (HDAC6) inhibitor developed by CKD Pharm worldwide, excluding Korea.
Product Name : CKD-510
Product Type : Other Small Molecule
Upfront Cash : $80.0 million
July 11, 2023
Lead Product(s) : CKD-510
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,305.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
S. Korea's Nafabeltan gets clinical approval for COVID-19 treatment in Australia
Details : The drug, Nafabeltan, will be administered to patients as part of the Australian government-led clinical study to find a COVID-19 treatment. The drug is currently used as a blood anticoagulant and acute pancreatitis treatment.
Product Name : Nafabeltan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chong Kun Dang Proceeds to Phase 2 Trial in Russia to Treat Covid-19
Details : Russia’s Drug Ministry approved of its clinical phase two trial design targeting some 100 seriously afflicted COVID-19 pneumonic patients there. The patients will be administered nafamostat for 10 days.
Product Name : Nafabeltan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2020
Lead Product(s) : Nafamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
